X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3040) 3040
Publication (153) 153
Book Review (51) 51
Book Chapter (22) 22
Magazine Article (6) 6
Book / eBook (4) 4
Conference Proceeding (3) 3
Data Set (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2775) 2775
female (1507) 1507
male (1419) 1419
index medicus (1235) 1235
middle aged (970) 970
aged (906) 906
antithrombins - adverse effects (796) 796
adult (713) 713
antithrombins - therapeutic use (712) 712
hematology (631) 631
anticoagulants - adverse effects (610) 610
risk factors (519) 519
anticoagulants (515) 515
anticoagulants - therapeutic use (510) 510
treatment outcome (490) 490
peripheral vascular disease (481) 481
hemorrhage - chemically induced (476) 476
dabigatran (475) 475
antithrombins - administration & dosage (463) 463
heparin - adverse effects (436) 436
cardiac & cardiovascular systems (416) 416
heparin (379) 379
thrombosis (357) 357
animals (349) 349
blood coagulation - drug effects (340) 340
aged, 80 and over (320) 320
thrombin (320) 320
warfarin (319) 319
anticoagulants - administration & dosage (318) 318
antithrombin (306) 306
recombinant proteins - therapeutic use (300) 300
heparin - therapeutic use (288) 288
surgery (279) 279
time factors (279) 279
benzimidazoles - adverse effects (278) 278
coagulation (277) 277
beta-alanine - analogs & derivatives (269) 269
adolescent (252) 252
antithrombin iii - analysis (248) 248
venous thromboembolism (241) 241
atrial fibrillation - drug therapy (239) 239
prospective studies (235) 235
therapy (232) 232
antithrombin-iii (231) 231
atrial fibrillation (228) 228
risk (227) 227
antithrombin iii (225) 225
thrombocytopenia - chemically induced (224) 224
abridged index medicus (219) 219
anticoagulation (219) 219
dabigatran - adverse effects (217) 217
pharmacology & pharmacy (216) 216
administration, oral (213) 213
retrospective studies (213) 213
peptide fragments - therapeutic use (210) 210
thromboembolism (209) 209
antithrombin iii - metabolism (207) 207
beta-alanine - adverse effects (207) 207
stroke (204) 204
thrombosis - etiology (200) 200
recombinant proteins - adverse effects (197) 197
medicine, general & internal (188) 188
prevention (188) 188
thrombosis - prevention & control (186) 186
dose-response relationship, drug (183) 183
hirudins - adverse effects (182) 182
heparin - administration & dosage (179) 179
rivaroxaban (177) 177
stroke - prevention & control (171) 171
bivalirudin (168) 168
drug therapy (165) 165
bleeding (164) 164
atrial fibrillation - complications (162) 162
analysis (161) 161
blood coagulation tests (161) 161
plasma (160) 160
care and treatment (159) 159
antithrombins - pharmacology (158) 158
peptide fragments - adverse effects (156) 156
warfarin - adverse effects (155) 155
child (153) 153
partial thromboplastin time (153) 153
atrial-fibrillation (152) 152
mortality (152) 152
blood coagulation (146) 146
molecular-weight heparin (145) 145
fibrinolysis (144) 144
anticoagulants - pharmacology (143) 143
cardiopulmonary bypass (141) 141
dabigatran etexilate (141) 141
fibrinolytic agents - therapeutic use (139) 139
management (139) 139
risk assessment (138) 138
unfractionated heparin (138) 138
health aspects (134) 134
percutaneous coronary intervention (134) 134
antithrombin iii - therapeutic use (131) 131
benzimidazoles - therapeutic use (130) 130
disseminated intravascular coagulation (130) 130
platelet aggregation inhibitors - therapeutic use (128) 128
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2823) 2823
German (83) 83
French (48) 48
Japanese (28) 28
Russian (16) 16
Spanish (15) 15
Italian (8) 8
Norwegian (8) 8
Polish (8) 8
Danish (7) 7
Hungarian (7) 7
Swedish (5) 5
Czech (3) 3
Bulgarian (2) 2
Chinese (2) 2
Portuguese (2) 2
Turkish (2) 2
Arabic (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1336 - 1346
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 21, pp. 2218 - 2230
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2013, Volume 34, Issue 7, pp. 489 - 500
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous... 
Novel oral anticoagulants | Bleeding | Management | RECOMBINANT FACTOR-VIIA | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | RANDOMIZED EVALUATION | INTRACRANIAL HEMORRHAGE | ACTIVATED FACTOR-VII | FACTOR-XA INHIBITOR | DABIGATRAN ETEXILATE | VENOUS THROMBOEMBOLISM | PROTHROMBIN COMPLEX CONCENTRATE | NONVALVULAR ATRIAL-FIBRILLATION | Plasma | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Antithrombins - administration & dosage | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | beta-Alanine - pharmacology | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Acute Disease | beta-Alanine - adverse effects | Administration, Oral | Morpholines - administration & dosage | Risk Factors | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Anticoagulants - pharmacology | Antithrombins - adverse effects | Blood Coagulation Tests | Benzimidazoles - pharmacology | Aged | Hemostatics - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Renal Dialysis
Journal Article
Journal of Neurology, Neurosurgery and Psychiatry, ISSN 0022-3050, 03/2018, Volume 89, Issue 3, pp. 263 - 270
Journal Article